title: Recent Advances in the Prophylaxis and Treatment of Malaria.
abstract: Increases in international travel and escalating drug resistance are putting put a growing number of travelers at risk of contracting malaria. Resistance to chloroquine and proguanil and real and perceived intolerance to standard agents, such as mefloquine, has highlighted the need for new antimalarials to prevent and treat malaria. Promising new agents to prevent malaria include the combination of atovaquone and proguanil, primaquine, and a related 8-aminoquinoline, tafenoquine. These agents are active against the liver stage of the malaria parasite, and therefore can be discontinued shortly after the traveler leaves the malaria-endemic area; this offers a clear advantage, in terms of adherence to a treatment regimen. For treatment of multidrug-resistant Plasmodium falciparum malaria, the combination of artemisinin derivatives plus mefloquine, or atovaquone plus proguanil, are the most active drug regimens.
authors.affiliation: Department of Medicine, Tropical Disease Unit, University Health Network, University of Toronto, 200 Elizabeth Street, EN G 224, Toronto, ON, Canada, M5G 2C4. kevin.kain@uhn.on.ca.
authors.forename: Annie-Claude
authors.initials: AC
authors.lastname: Labbé
authors.forename: Mona R.
authors.initials: MR
authors.lastname: Loutfy
authors.forename: Kevin C.
authors.initials: KC
authors.lastname: Kain